1. Home
  2. ADVM vs CUPR Comparison

ADVM vs CUPR Comparison

Compare ADVM & CUPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ADVM
  • CUPR
  • Stock Information
  • Founded
  • ADVM 2006
  • CUPR 2019
  • Country
  • ADVM United States
  • CUPR Singapore
  • Employees
  • ADVM N/A
  • CUPR N/A
  • Industry
  • ADVM Biotechnology: Biological Products (No Diagnostic Substances)
  • CUPR
  • Sector
  • ADVM Health Care
  • CUPR
  • Exchange
  • ADVM Nasdaq
  • CUPR NYSE
  • Market Cap
  • ADVM 47.4M
  • CUPR 43.2M
  • IPO Year
  • ADVM 2014
  • CUPR 2025
  • Fundamental
  • Price
  • ADVM $2.74
  • CUPR $7.57
  • Analyst Decision
  • ADVM Strong Buy
  • CUPR
  • Analyst Count
  • ADVM 5
  • CUPR 0
  • Target Price
  • ADVM $23.80
  • CUPR N/A
  • AVG Volume (30 Days)
  • ADVM 297.2K
  • CUPR 418.4K
  • Earning Date
  • ADVM 08-11-2025
  • CUPR 01-01-0001
  • Dividend Yield
  • ADVM N/A
  • CUPR N/A
  • EPS Growth
  • ADVM N/A
  • CUPR N/A
  • EPS
  • ADVM N/A
  • CUPR N/A
  • Revenue
  • ADVM $1,000,000.00
  • CUPR $35,406.00
  • Revenue This Year
  • ADVM N/A
  • CUPR N/A
  • Revenue Next Year
  • ADVM $18.82
  • CUPR N/A
  • P/E Ratio
  • ADVM N/A
  • CUPR N/A
  • Revenue Growth
  • ADVM N/A
  • CUPR N/A
  • 52 Week Low
  • ADVM $1.78
  • CUPR $3.51
  • 52 Week High
  • ADVM $10.14
  • CUPR $7.60
  • Technical
  • Relative Strength Index (RSI)
  • ADVM 59.62
  • CUPR N/A
  • Support Level
  • ADVM $2.50
  • CUPR N/A
  • Resistance Level
  • ADVM $2.75
  • CUPR N/A
  • Average True Range (ATR)
  • ADVM 0.20
  • CUPR 0.00
  • MACD
  • ADVM 0.06
  • CUPR 0.00
  • Stochastic Oscillator
  • ADVM 82.50
  • CUPR 0.00

About ADVM Adverum Biotechnologies Inc.

Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.

About CUPR CUPRINA HOLDINGS (CAYMAN) LIMITED

Cuprina Holdings (Cayman) Ltd is a biomedical and biotechnology company that is dedicated to the development and commercialization of products for the management of chronic wounds, as well as operating in the health and beauty sector. It manufactured and distributed a line of medical grade sterile blowfly larvae bio-dressing products marketed under the MEDIFLY brand name, or the MEDIFLY products. The MEDIFLY products are used as a biological debridement tool for chronic wounds, in a procedure known as Maggot Debridement Therapy, or MDT, which is an effective alternative to surgical debridement.

Share on Social Networks: